의약품 및 바이오테크놀러지의 옵션 및 평가 계약(2019-2026년)

Benchmark Option-Based Partnership Strategies Across the Global Biopharma Industry

Free report sample

The Option and Evaluation Deals in Pharmaceuticals and Biotechnology 2019-2026 report provides a comprehensive analysis of option-based partnering agreements across the global life sciences industry. Designed for business development, licensing, and strategy professionals, the report delivers detailed insight into how companies structure option and evaluation partnerships, negotiate financial terms, and manage the transfer of development and commercialization rights.

Fully revised and updated, the report analyzes option and evaluation deals announced between 2019 and 2026, providing a detailed view of how pharmaceutical and biotechnology companies use option agreements to evaluate technologies, reduce development risk, and secure future licensing rights.

Each transaction includes financial information where available and links to detailed online deal records. Where agreements have been publicly filed, the report also provides access to the underlying contract documents submitted to regulators, enabling deeper insight into the detailed terms negotiated between partners.

By combining detailed deal data, financial benchmarking, and access to real contract agreements, the report provides valuable intelligence for evaluating potential partners, structuring option deals, and negotiating stronger agreements.

Key Benefits

• Save Significant Research Time

Access a comprehensive database of option and evaluation deals instead of searching multiple databases, press releases, and regulatory filings.

• Benchmark Option and Evaluation Deal Structures

Understand how pharmaceutical and biotechnology companies structure option-based partnerships, including evaluation rights, development options, and licensing pathways.

• Analyze Financial Terms with Confidence

Review disclosed payment structures and deal terms to benchmark the financial value and structure of comparable option transactions.

• Access Real Contract Documents

Where available, explore actual option and evaluation agreements filed with the SEC, providing deeper insight into the contractual provisions behind real-world deals.

• Identify the Most Active Option Dealmakers

Discover which companies are most active in option-based partnerships and analyze their strategic partnering activity.

• Track Industry Trends

Analyze option and evaluation dealmaking trends since 2019 across companies, therapeutic areas, and technology types.

What's Included in the Report

Analysis of option and evaluation dealmaking trends since 2019

Overview of option deal structures and evaluation partnership models

Review of leading option and evaluation deals by headline value

Profiles of the top 25 most active option and evaluation dealmakers

Detailed analysis of deals organized by company, therapeutic area, technology type, and industry sector

A comprehensive deal directory covering option and evaluation agreements announced since 2019

Links to online deal records and contract documents where available

Due Diligence Insights from Real Agreements

By reviewing actual option and evaluation contracts, the report enables users to evaluate key partnership provisions such as:

• Option rights and evaluation periods
• Financial payment structures and option fees
• Development milestones and licensing triggers
• Intellectual property ownership and licensing rights
• Development and commercialization responsibilities
• Contract duration and termination provisions
• Contract documents provide valuable insight into the detailed terms negotiated between companies-information often not disclosed in press releases or standard deal databases.
• Why This Report Matters
• Option and evaluation agreements are widely used by pharmaceutical and biotechnology companies to assess promising technologies while limiting early-stage risk. These deals provide companies with the opportunity to evaluate assets before committing to full licensing or acquisition agreements.
• By combining comprehensive deal data, financial benchmarking, and access to real contract documents, this report provides the intelligence needed to structure stronger option partnerships, evaluate emerging technologies, and negotiate more effectively.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in option and evaluation dealmaking

• 2.1. Introduction
• 2.2. Definition of option and evaluation deal
• 2.3. Trends in option and evaluation deals since 2019
  • 2.3.1. Option and evaluation dealmaking by year
  • 2.3.2. Option and evaluation dealmaking by phase of development
  • 2.3.3. Option and evaluation dealmaking by industry sector
  • 2.3.4. Option and evaluation dealmaking by therapy area
  • 2.3.5. Option and evaluation dealmaking by technology type
  • 2.3.6. Option and evaluation dealmaking by most active company
• 2.4. Reasons for entering into option and evaluation partnering deals
• 2.5. The future of option and evaluation deals

Chapter 3 - Overview of option and evaluation deal structure

• 3.1. Introduction
• 3.2. Option and evaluation agreement structure

Chapter 4 - Leading option and evaluation deals

• 4.1. Introduction
• 4.2. Top option and evaluation deals by value

Chapter 5 - Top 25 most active option and evaluation dealmakers

• 5.1. Introduction
• 5.2. Top 25 most active option and evaluation dealmakers

Chapter 6 - option and evaluation deals including contracts directory

• 6.1. Introduction
• 6.2. Option and evaluation deals with contracts
• Deal directory
• Deal directory - option and evaluation dealmaking by companies A-Z
• Deal directory - option and evaluation dealmaking by therapy area
• Deal directory - option and evaluation dealmaking by technology type
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

TABLE OF FIGURES

• Figure 1: Definition of option and evaluation
• Figure 2: Trends in option and evaluation deal announcements
• Figure 3: Option and evaluation deals signed at each phase of development
• Figure 4: Option and evaluation deals by industry sector
• Figure 5: Option and evaluation deals by therapy area
• Figure 6: Option and evaluation deals by technology type
• Figure 7: Top 25 most active option and evaluation dealmakers
• Figure 8: Top option and evaluation deals by value
• Figure 9: Most active option and evaluation dealmakers